EnovisENOV +1.09%61 OCF Margin % is 4.07% as of Mar. 2026, which is 54% below its 10-year median of 8.79. GuruFocus rates ENOV with a GF Score™ of 61/100 and a GF Value™ of $49.60 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Enovis ranks better than 59.51% on this metric.
The historical rank and industry rank for Enovis's OCF Margin % or its related term are showing as below:
ENOV'
s OCF Margin % Range Over the Past 10 Years
Min: -3.57 Med: 8.79 Max: 26.94
Current: 10.66
During the past 13 years, the highest OCF Margin % of Enovis was 26.94%. The lowest was -3.57%. And the median was 8.79%.
ENOV's OCF Margin % is ranked better than 59.51% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: 5.86
vs ENOV: 10.66
Enovis OCF Margin % Related Terms
Enovis OCF Margin % Historical Data
* Premium members only.
The historical data trend for Enovis's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Enovis's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enovis OCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Enovis's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Enovis's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enovis (ENOV) has a OCF Margin % of 4.07% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Enovis and its competitors. This is 54% below median its historical median of 8.79. According to the industry distribution chart, Enovis ranks #330 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 40.5%.
Is Enovis' OCF Margin % too high?
Enovis' current OCF Margin % of 4.07% is 54% below median its 10-year median of 8.79. The Medical Devices & Instruments industry median OCF Margin % is 5.86. Enovis' value of 4.07% is 30.5% below this industry median. Based on the distribution chart, Enovis ranks #330 out of 815 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Enovis has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Enovis' OCF Margin % compare to IART and AHCO?
According to the Medical Devices & Instruments industry distribution chart, Enovis ranks #330 out of 815 companies for OCF Margin %. This puts Enovis in the upper half of its industry. The industry median OCF Margin % is 5.86. Enovis' value of 4.07% is 30.5% below this benchmark. While the company's 10-year median is 8.79 vs. the industry median of 5.86, Enovis has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Devices & Instruments company?
The median OCF Margin % among Medical Devices & Instruments companies is 5.86, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Enovis's current OCF Margin % of 4.07% is 30.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Enovis and its competitors. For the Medical Devices & Instruments industry, the median OCF Margin % is 5.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enovis's current OCF Margin % is 4.07%, which is 54% below median its own 10-year median of 8.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enovis stock overvalued right now?
Based on GuruFocus' analysis, Enovis (ENOV) is currently considered Possible Value Trap. The stock's GF Value™ is $49.60, compared to a current price of $21.38 — trading 56.9% below its estimated fair value. The current OCF Margin % is 4.07%, which is 54% below median its 10-year median of 8.79 and 30.5% below the Medical Devices & Instruments industry median of 5.86. Enovis' overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Enovis (ENOV), the current OCF Margin % is 4.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enovis (ENOV) Overvalued in 2026?
Based on GuruFocus' analysis, Enovis stock appears to be undervalued.
The current stock price of $21.38 is trading 56.9% below its estimated GF Value™ of $49.60.
GuruFocus considers Enovis to be Possible Value Trap.
Key valuation signals for ENOV:
OCF Margin %: 4.07% (54% below median its 10-year median of 8.79)
GF Value™: $49.60 vs. price of $21.38 (56.9% below fair value)
Industry Position: 30.5% below the Medical Devices & Instruments median (#330 of 815)
No single metric tells the full story. See the ENOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.
61GF Score
Get the complete analysis for ENOV
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ENOV has been successfully added to your 
